Design Therapeutics Inc expected to post a loss of 28 cents a share - Earnings Preview

Design Therapeutics

02/05/2025 12:19

Design Therapeutics Inc DSGN.OQ DSGN.O is expected to show no change in quarterly revenue when it reports  results on May 6 (estimated) for the period ending March 31 2025

‚ÄčLSEG's mean analyst estimate for Design Therapeutics Inc is for a loss of 28 cents per share.

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ‚Äč

Wall Street's median 12-month price target for Design Therapeutics Inc is $5.00‚Äč, above‚Äč its last closing price of $4.71. ‚Äč‚Äč‚Äč

Previous quarterly performance (using preferred earnings measure in US dollars). ‚Äč

QUARTER ENDING
STARMINESMARTESTIMATE¬ģ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.27
-0.24
Beat
10
Sep. 30 2024
-0.22
-0.24
-0.23
Beat
5.5
Jun. 30 2024
-0.21
-0.23
-0.21
Beat
10‚Äč
Mar. 31 2024
-0.25
-0.26
-0.20
Beat
24.1
‚Äč‚ÄčDec. 31 2023
-0.31
-0.21
Beat
32.2
Sep. 30 2023
-0.38
-0.41
-0.28
Beat
31.5‚Äč
Jun. 30 2023
-0.39
-0.40
-0.36
Beat
9.4
Mar. 31 2023
-0.36
-0.36
-0.35
Beat
2.6

This summary was machine generated May 2 at 11:19 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)